Numerous studies and clinical trials have investigated the efficacy of laetrile as a cancer treatment. The consensus among scientific and regulatory bodies, including the Food and Drug Administration (FDA) and the National Cancer Institute (NCI), is that laetrile is not an effective treatment for cancer. Large-scale studies have shown no significant benefit in terms of tumor reduction or increased survival rates. Moreover, the risks associated with laetrile use, particularly cyanide toxicity, outweigh any unproven benefits.
